Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 1 | Unknown | — |
The patient took fourth dose eight days after first dose of Vivotif; Case reference number US-BN-2025-000128 is a spontaneous case initially received from consumer via Emergent BioSolutions (reference number: EMG2025-032) on 14-Jan-2025 and concerns male patient of unspecified age. The patient's medical history and concomitant medication details were not provided. On 05-Jan-2025, the patient took first dose of Vivotif vaccine (batch number: unknown), at an unknown dose, route or site of administration for unknown indication. On 07-Jan-2025, two days after the first dose, the patient took second dose of Vivotif vaccine (batch number: unknown), at an unknown dose, route or site of administration. On 09-Jan-2025, four days after the first dose, the patient took third dose of Vivotif vaccine (batch number: unknown), at an unknown dose, route or site of administration. On 13-Jan-2025, eight days after the first dose, the patient took fourth dose of Vivotif vaccine (batch number: unknown), at an unknown dose, route or site of administration (explicitly coded as 'Inappropriate schedule of vaccine administered'). At the time of initial report, it was unknown if the patient experienced any adverse events due to Vivotif. No further information was provided.; Reporter's Comments: A male patient of unspecified age took the fourth dose of Vivotif vaccine on the day 8 after the first dose, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A male patient of unspecified age took the fourth dose of Vivotif vaccine on the day 8 after the first dose, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None